Director Dealing

RNS Number : 0606R

Scancell Holdings Plc

02 November 2021

 

2 November 2021

Scancell Holdings plc

("Scancell" or the "Company")

Director Dealing

Scancell (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious diseases, announces that Vulpes Life Science Fund, a person closely associated with Martin Diggle, Non-Executive Director of the Company, has purchased 100,000 ordinary shares of 0.1 pence each ("Ordinary Shares") in the Company on 29 October 2021 at a price of 19 pence per share. Following the purchase, Vulpes Life Science Fund holds 117,279,029 Ordinary Shares representing 14.4% of the Company's issued share captial.

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING

MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Vulpes Life Science Fund
2	Reason for the notification
a)	Position/status	Person closely associated with Martin Diggle, Non-Executive Director
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Scancell Holdings plc
b)	LEI	2138008RXEG856SNP666
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary Shares of 0.1 pence each
b)	Identification Code	GB00B63D3314
c)	Nature of the transaction	Purchase of Ordinary Shares
d)	Price(s) and volume(s)	100,000 Ordinary Shares 19 pence per Ordinary Share
e)	Aggregated information - Aggregated volume - Price	N/A (single transaction)
f)	Date of the transaction	29 October 2021
g)	Place of the transaction	London Stock Exchange, AIM

- ENDS -

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR).

For more information, please contact:

For further information, please contact:
Scancell Holdings plc	[phone]
Dr John Chiplin, Executive Chairman
Professor Lindy Durrant, CEO
Panmure Gordon (UK) Limited (Nominated Adviser and Joint Broker)	[phone]
Freddy Crossley/Emma Earl (Corporate Finance)
Rupert Dearden (Corporate Broking)
Stifel Nicolaus Europe Limited (Joint Broker)	[phone]
Nicholas Moore/Samira Essebiyea (Healthcare Investment Banking)
Nick Adams (Corporate Broking)
FTI Consulting	[phone]
Simon Conway/Natalie Garland-Collins

Notes for Editors

About Scancell

Scancell is developing novel immunotherapies for the treatment of cancer based on its technology platforms, ImmunoBody^®, Moditope^® and AvidiMab^TM, with four products in multiple cancer indications and development of a vaccine for COVID-19.

ImmunoBody^® vaccines target dendritic cells and stimulate both CD4 and CD8 T cells with the ability to identify, target and eliminate cancer cells. These cancer vaccines have the potential to be used as monotherapy or in combination with checkpoint inhibitors and other agents. The Directors believe that this platform has the potential to enhance tumour destruction, prevent disease recurrence and extend survival.

DNA vaccine against COVID-19: As research data emerges, it is becoming increasingly clear that the induction of potent and activated T cells may play a critical role in the development of long-term immunity and clearance of virus-infected cells. Initial research is underway and Scancell has initiated a Phase 1 clinical trial known as COVIDITY in October 2021.

Moditope^® represents a completely new class of potent and selective immunotherapy agents based on stress-induced post-translational modifications (siPTM). Examples of such modifications are citrullination, an enzyme-based conversion of arginine to citrulline, and homocitrullination (or carbamylation), in which lysine residues are converted to homocitrulline. Expression of peptides containing these modifications have been demonstrated to induce potent CD4 cytotoxic T cells to eliminate cancer. The Directors believe that this platform has the potential to eradicate hard to treat solid tumours.

AvidiMab™ has broad potential to increase the avidity or potency of any therapeutic monoclonal antibody (mAb) including those being developed for autoimmune diseases, as well as cancer. Scancell's development pipeline includes mAbs against specific tumour-associated glycans (TaGs) with superior affinity and selectivity profiles, that have now been further engineered using the Company's AvidiMab™ technology; this confers the Scancell anti-TaG mAbs with the ability to directly kill tumour cells. The mAbs targeting TaGs can also be used to deliver cytotoxic payload to cancer or to redirect T cells.

 

END

 

 

DSHEAEFAEELFFFA